These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

15978 related items for PubMed ID: 25823918

  • 1. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH.
    Cancer Med; 2015 May 01; 4(5):661-72. PubMed ID: 25619164
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H, Nakagawa K.
    Int J Clin Oncol; 2020 May 01; 25(5):818-830. PubMed ID: 31549270
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive markers for the new immunotherapies.
    Mahoney KM, Atkins MB.
    Oncology (Williston Park); 2014 Nov 01; 28 Suppl 3():39-48. PubMed ID: 25384886
    [Abstract] [Full Text] [Related]

  • 8. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T, Gray JE, Antonia SJ.
    Expert Opin Biol Ther; 2017 Mar 01; 17(3):305-312. PubMed ID: 28064556
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K, Daud AI.
    Cancer J; 2017 Mar 01; 23(1):3-9. PubMed ID: 28114249
    [Abstract] [Full Text] [Related]

  • 10. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.
    Pharmacotherapy; 2015 Oct 01; 35(10):963-76. PubMed ID: 26497482
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA.
    J Oncol Pharm Pract; 2015 Dec 01; 21(6):451-67. PubMed ID: 24917416
    [Abstract] [Full Text] [Related]

  • 12. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF, Shachar SS, Nyrop KA, Muss HB.
    Oncologist; 2017 Apr 01; 22(4):470-479. PubMed ID: 28275115
    [Abstract] [Full Text] [Related]

  • 13. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct 01; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L, Liu Y, Wang Y.
    Oncologist; 2019 Feb 01; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [Abstract] [Full Text] [Related]

  • 15. Immune checkpoint blockade.
    Naidoo J, Page DB, Wolchok JD.
    Hematol Oncol Clin North Am; 2014 Jun 01; 28(3):585-600. PubMed ID: 24880949
    [Abstract] [Full Text] [Related]

  • 16. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A, Burns TF.
    J Hematol Oncol; 2017 Apr 24; 10(1):87. PubMed ID: 28434399
    [Abstract] [Full Text] [Related]

  • 17. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.
    Immunotherapy; 2015 Apr 24; 7(7):777-92. PubMed ID: 26250412
    [Abstract] [Full Text] [Related]

  • 18. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A, Patel SP, Kurzrock R.
    Nat Rev Clin Oncol; 2017 Apr 24; 14(4):203-220. PubMed ID: 27805626
    [Abstract] [Full Text] [Related]

  • 19. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.
    Eur Urol; 2015 Aug 24; 68(2):267-79. PubMed ID: 25824720
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM, Carvajal RD.
    Curr Oncol Rep; 2017 Jul 24; 19(7):45. PubMed ID: 28508938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 799.